Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 05, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals Inc., USA, the US arm of Glenmark Pharmaceuticals, has launched Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL) in single-dose vials in the United States. Lacosamide is used in the treatment of partial-onset seizures and status epilepticus. The launch expands Glenmark's portfolio of injectable products in the US generics market, adding to its existing neurology offering. This follows the typical commercialisation path after receiving USFDA approval for the product.
The new product addition strengthens Glenmark's US injectables business and adds a new revenue stream in the generics segment, though the immediate financial impact is expected to be modest given the competitive nature of the US generics market.